Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Dreimer200on Mar 30, 2022 5:41pm
227 Views
Post# 34560719

RE:RE:RE:RE:Soon

RE:RE:RE:RE:Soon
99942: Not sure I agree with you about “soon.” Unfortunately, I did not speak with the company – I am relying on a couple of posters who said they had been told there would be a news release “soon.” “Soon” suggests within a couple of weeks. If the company knowledge is, in fact, so limited, perhaps it would be better to disavow all attempts at prediction and simply say:  “We have no information at the moment. We have decided to scrap the newsletter. We will, of course, release any information about the progress of the company as soon as it becomes available.” That would indicate that  they are waiting for information over which they have no control. They should avoid words which lead to reasonable, but doomed expectations. 
 
I will confess that my little diatribe is a reflection of an annoyance built up over a number of years. (I am now so old a shareholder that 70-year-old ladies give up their seats to me on the bus. Or they would -- if I could make it to the bus stop.)
 
You hold out some  tantalizing prospects – of the kind which no long-term Theralase shareholder can afford to entertain. We have become used  to disappointment, and know the folly of optimistic expectations.
 
Yes, one day – perhaps even this year – we will see news of positive clinical results, official FDA encouragement, and some move in the direction (I am being so cautious) of a clinical trial for a different type of cancer. And that might involve some kind of partnership. One day – as a result of such events – the stock price might go up. A little bit. But I am going to avoid the word “soon.”
 
–Idel Dreimer
<< Previous
Bullboard Posts
Next >>